Px Wire September 2023
Volume 13, Number 3
DPP Audience & Provider Insights for the DPP Research and Marketing Plan: Phase 1 Research Findings
This report, by M&C Saatchi World Services, AVAC, and partners, highlights learnings from Human-Centered Design Research undertaken in 2022 to understand the values and motivations of potential users and influencers of the Dual Prevention Pill (DPP) in Kenya, South Africa, and Zimbabwe.
Dual Prevention Pill: Market Preparation and Introduction Strategy
This strategy, updated in August 2023, is intended for donors, governments, implementing partners and civil society to inform priorities and planning for DPP rollout. The strategy describes activities required to build a cohesive body of evidence and recommends an approach to DPP introduction to focus efforts. Where possible, activities will be embedded into existing programs to consolidate and leverage resources.
HIV Prevention Choice Manifesto
The HIV Prevention Choice Manifesto emphasizes community-led leadership and the importance of choice in HIV prevention for African women and girls. The manifesto advocates for universal access to a broad range of biomedical tools for HIV prevention and underscores the transformative potential when African women and girls lead advocacy and response efforts in HIV healthcare.
More information and background on the manifesto is available on our blog.
Px Wire May 2023
Volume 13, Number 2
PrEP Tracker data, preparing for new products, the HIV prevention pipeline and our prevention playlist. All that and more in the latest issue of PxWire.
HIV Prevention Research & Development Investments 2021
In its 17th annual report, the Resource Tracking for HIV Prevention Research & Development Working Group documents research and development spending for the calendar year 2021. This report also analyzes funding trends spanning 22 years for the following biomedical HIV prevention options: preventive HIV vaccines, microbicides, pre-exposure prophylaxis (PrEP), treatment as prevention (TasP), voluntary medical male circumcision (VMMC), female condoms and prevention of vertical transmission (PVT). More information at hivresourcetracking.org.
Global Investment in HIV Cure Research & Development in 2021
A decade of progress
AVAC Partnership Strategy 2023-2026
This document lays out AVAC’s plan to transition away from traditional power structures when working with partners — from civil society advocates to scientists, policy makers, program implementers, and more. AVAC strives towards a model in which those with lived experience and field expertise have influence and equal voice in the design and delivery of plans and priorities.
CASPRiffic: March 2023 edition
See here the March 2023 edition of CASPRiffic. CASPRiffic is a monthly round-up of all that happened CASPR-related and what’s to come in the coming months.
Px Wire February 2023
Volume 13, Number 1
This issue offers data from Q4 of 2022, when South Africa became the fourth country in the world to approve injectable cabotegravir (CAB) for PrEP; the dapivirine vaginal ring (DVR) was approved in a growing number of countries; and oral PrEP use was on the rise, passing the mark of 3.8 million initiations. For the first time, the world has multiple biomedical interventions to offer choice, and it’s essential to develop the programs that bring the fruits of science to the communities facing public health threats, while continuing to invest in developing new options to meet diverse needs.